The drug was developed as part of an innovative and successful study, following which the FDA declared it a breakthrough and put it on an accelerated track for approval. In Israel, only about 2% of the treatments of the future at the forefront of science in the fight against cancer are available, when about 11,000 die from this serious disease every year.
15% of the breast cancer patient population is professionally defined as "triple negative". This is a particularly violent type of breast cancer and the success rates of the standard treatment are only a few percent. Following Innovative research And the recent successful FDA declared the drug in question a "breakthrough" and put it on an "expedited track" for approval. The reason for its entry into an accelerated track is in light of the impressive results of the study: approximately 15 times the therapeutic success rate compared to the standard treatment in this seriously ill population and even more when it comes to metastatic patients.
Nir Erez, the operator of a new service for cancer patients, reveals that the participation of a cancer patient in the groundbreaking research results in significant financial savings both for the patient himself and for the country itself, since there is no need for an expensive test for genetic mutations or another biological test on the tumor tissue since the treatment is suitable for about 90% from the sick and you just have to accept it. This is another example, according to Nir Erez, of the type of personalized treatments for a specific patient that arise as part of the work of the Trail in Pharma company, which offers tens of thousands of cancer patients in Israel hope and participation in groundbreaking research around the world. According to him, a similar case happened to his mother and no one brought up the possibility of testing around the world to find customized studies.
Erez reveals that every year in Israel approximately 11,000 people die of cancer and between 25,000 and 30,000 new cancer patients are diagnosed. In total, according to the data of the Ministry of Health, there are over 100,000 cancer patients in Israel who are treated by only 240 oncologists under a huge burden and an acute lack of standards. According to him, patients must be aware of the situation and take responsibility for managing the disease in search of the 'golden heart flower' - that successful cure or treatment for cancer that is not necessarily found in the standard treatments offered to them.
In this situation, when the support system does not have the ability to meet the needs of the patients, those for their part should know that they must act to obtain information about additional treatments available around the world, including Israel. Nir emphasizes that patients and their companions must not miss 'under the radar' treatments that can suit them better than any other treatment and that when they have this information, they will choose the best treatment with the oncologist. Cancer, emphasizes Nir Erez, is a complex disease and the patients are not a 'copy-paste' of each other and therefore, the same search should be tailored to the overall medical background of the cancer patient and not just to a mutation that may exist in his tumor cells.
About 15,000 cancer studies with the latest cancer drugs and the most advanced approaches are currently available worldwide. This is when the medical system in Israel is only exposed to about 2% of the research at the forefront of science in the fight against cancer. Search and research work between these studies is a complex and professional task that Nir Erez offers.
The new service - TRIAL-IN Pharma - helps cancer patients find and receive treatments that are at the forefront of science in addition to the standard protocols offered to them. Access to these treatments, some of which have been defined as 'groundbreaking' by the health authorities, such as the FDA, is made possible mainly in research and compassion frameworks all over the world. Through the service, the patient can receive these treatments today, for free, and with the chance to profit from them years before they are approved and available in the health basket. The service continues with the professional-medical accompaniment of the patient and the oncologist, until the treatment is obtained anywhere and from anywhere in the world.
The service was initiated by Nir Erez, who has extensive background and knowledge in the field of cancer, many years of familiarity with oncologists and the various treatments. By Nir's side in the service, a team of 7 senior oncologists. According to him, it is not new that the health system has reached the limit of its capacity, and despite its efforts, the plight of cancer patients cries out to the heavens.
The service that Trail In Pharma offers is a personalized test for research and compassion in Israel and around the world. Thorough navigation work in an ocean of studies registered in the world in the field of cancer and is done under a strict quality control process. Later, Trail-in Pharma accompanies the relationship with the pharmaceutical companies and medical centers, until the treatment is received. Nir emphasizes that cancer is a complex disease and each patient has a unique treatment resulting from his specific type of tumor, the biological profile of the tumor, surgeries, previous treatments and more. The oncologist has a central role in choosing the treatment for the patient when the goals of the treatment are to save life, prolong life and maintain a good quality of life for the patient.
3 תגובות
To Moses, I wish.
Kind of an advertising section
The visualization in the picture is of a "cancerous tumor" and not of a "cancerous cell".
The cancerous cell looks like a normal cell, the cancerous tumor is a culture of cells from which invasive cells come out in all directions which form the extensions.
The invasive cell, apart from the property that it is a cell that multiplies without control and has also lost the ability to self-destruct, has another property that it is able to dissolve the intercellular connective tissue (collagen) and migrate out of the tumor.
The cells that migrate from the tumor out form the extensions in the form of "legs" therefore the cancerous tumor looks like a cancer with legs and hence the name of the disease.